Skip to content
Search

Latest Stories

Dhawan, Pujara centuries hurt Sri Lanka in first Test

Shikhar Dhawan smashed a career-best 190 on his Test comeback to lead a brilliant Indian batting assault on the opening day of the first Test against Sri Lanka on Wednesday (26).

The left-handed opener struck 31 boundaries in a blazing 168-ball knock and Cheteshwar Pujara joined in with an unbeaten 144 to take the visitors to 399-3 at stumps.


The hosts toiled in the Galle field and suffered a major blow when all-rounder Asela Gunaratne broke his thumb trying to take a catch off Dhawan.

He is set to undergo a surgery Wednesday and is almost certain to miss the rest of the three-Test series.

Dhawan and Pujara put on 253 for the second wicket -- India's highest second-wicket stand against Sri Lanka -- after skipper Virat Kohli won the toss and chose to bat under an overcast sky.

Dhawan, drafted into the Indian squad at the last moment, said it was a blow to get out so close to a maiden double hundred.

"Of course I was disappointed that I got out for 190, I would have loved to have scored a 200," Dhawan said.

"But more than that, I got out at the wrong time. It was the last over before tea. But the way I was playing, I was confident that I could clear the mid-off fielder and I was almost hitting a boundary per over.

"I was in that zone and I backed myself. Unfortunately it didn't go my way."

Dhawan was out in the last over before tea when he handed a simple catch off paceman Nuwan Pradeep to Angelo Mathews at mid-off.

Kohli was dismissed for three when he tried to pull a chest-high delivery from Pradeep, who took three for 64, but nicked behind instead to Niroshan Dickwella.

Pradeep's appeal was initially turned down but the decision was overturned by the TV umpire when replays showed the ball had grazed Kohli's bat.

It was a blow but no major problem for India as Dhawan took the opening day honours, celebrating his return to Test cricket with a breathtaking array of shots.

It was the second time he had scored a century in a single Test session, having made 187 on his debut against Australia -- including 106 in one session.

Dhawan scored 126 off just 90 balls between lunch and tea, leaving Virender Sehwag as the only other Indian batsman to score more runs in a single session.

The 31-year-old got a standing ovation from teammates in the dressing room upon completing his fifth Test century.

The innings was especially sweet for Dhawan, who was made to sit out of India's last 11 Tests following a dip in form.

Dhawan's last Test century was at the same venue, during India's 2015 tour of the island nation. India lost the Galle match but went on to win the remaining two games to pocket the series 2-1.

The hosts squandered a golden chance to dismiss Dhawan in his thirties when Gunaratne dropped the batsman at second slip.

Medics rushed to attend to Gunaratne, who was writhing in pain before walking off the ground.

The Indians were given an early jolt when Dhawan's opening partner Abhinav Mukund edged Pradeep behind to Dickwella in the eighth over.

Mukund, who opened the batting after Lokesh Rahul was ruled out with illness, made 12.

But Dhawan toyed with the toothless Sri Lankan attack, at one point hitting new skipper Rangana Herath for two boundaries on the trot.

India handed a Test cap to all-rounder Hardik Pandya and Sri Lanka brought in batsman Danushka Gunathilaka for his debut.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less